Target
Monoglyceride lipase
Ligand
BDBM561356
Substrate
n/a
Meas. Tech.
MAGL Inhibitory Activity
IC50
52.0±n/a nM
Citation
 Benz, JGrether, UHornsperger, BKuhn, BRichter, HKocer, BO''Hara, FRitter, MTsuchiya, SCollin, LJohnson, SEBell, C Piperazine derivatives as MAGL inhibitors US Patent  US11390610 Publication Date 7/19/2022 
Target
Name:
Monoglyceride lipase
Synonyms:
HU-K5 | Lysophospholipase homolog | Lysophospholipase-like | MAGL | MGL | MGLL | MGLL_HUMAN
Type:
Hydrolase
Mol. Mass.:
33264.56
Organism:
Homo sapiens (Human)
Description:
Human recombinant MGL (Cayman Chemical, cat# 10008354).
Residue:
303
Sequence:
MPEESSPRRTPQSIPYQDLPHLVNADGQYLFCRYWKPTGTPKALIFVSHGAGEHSGRYEELARMLMGLDLLVFAHDHVGHGQSEGERMVVSDFHVFVRDVLQHVDSMQKDYPGLPVFLLGHSMGGAIAILTAAERPGHFAGMVLISPLVLANPESATTFKVLAAKVLNLVLPNLSLGPIDSSVLSRNKTEVDIYNSDPLICRAGLKVCFGIQLLNAVSRVERALPKLTVPFLLLQGSADRLCDSKGAYLLMELAKSQDKTLKIYEGAYHVLHKELPEVTNSVFHEINMWVSQRTATAGTASPP
  
Inhibitor
Name:
BDBM561356
Synonyms:
US11390610, Example 185
Type:
Small organic molecule
Emp. Form.:
C26H21N5O2S
Mol. Mass.:
467.542
SMILES:
O=C(N1CCN(CC1)c1nc2ccccc2c(=O)[nH]1)c1ccc2nc(sc2c1)-c1ccccc1
Structure:
Search PDB for entries with ligand similarity: